The Growth Opportunities Under Your Nose

Hot-shot growth stocks aren’t the only way to get decent capital returns…

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m generally rubbish at spotting small companies that are on the fast track to heady growth.
 
For proof, look no further than my decision in November 2013 that butchers’ shop chain Crawshaw looked too expensive at 13p. As I write, the shares are at 63p, and the company’s growth prospects apparently look exciting enough to encourage the UK head of supermarket chain Lidl to jump ship and run the business.
 
Which isn’t to say, I hasten to add, that my own portfolio doesn’t have its share of companies exhibiting a decent rate of growth, even though I’m primarily an income investor.

Recovery stocks

Compass Group, for instance, up 95% in four years. GKN, up 146% over roughly the same period. And pasty shop chain Greggs, up 185% in just over two years.

All decent returns I think, and all fairly predictable at the time of purchase — although, as I’ve said before, I have been surprised at the actual extent of Greggs’ stellar rise.
 
Why ‘predictable’? Because the approach I take to looking for growth shares is largely one of looking for shares with recovery potential.
 
Put another way, while I’m rubbish at spotting businesses like Crawshaw’s, I reckon I’m much better at spotting unloved, out-of-favour businesses that have temporarily been hit by headwinds.

Contrarian picks

And as a strategy for finding growth shares, it’s one with some fairly weighty factual evidence on its side.
 
Well-known contrarian investor David Dreman, for instance, has conducted a number of in-depth studies into the long-term performance of various investment strategies.
 
And again and again, a strategy of buying those unloved, out-of-favour businesses — and holding them until they recover — delivers startling outperformance.
 
Put another way, load up on shares with price-earnings (P/E) ratios at below the market average, hold until they reach market average — and then sell, and buy another unloved, out-of-favour business.

Growth + Yield: win both ways

Of course, you don’t have to sell. I don’t. I like to buy unloved, out-of-favour businesses with a decent dividend yield, and simply hold them as income stocks.

And, let’s face it, when a business is hit by adverse headwinds, a low P/E and a high yield often go hand in hand.
 
Nor do you have to look too far to see investors who’ve profited from this ‘buy cheap, hold for the long term’ strategy.
 
Warren Buffett’s fabled purchase of Coca-Cola in the late 1980s, for instance, falls into exactly this category.

347% vs. 42%: take your pick

Or, for a UK example, take Neil Woodford, who is now heading his own investment firm, of course. As I’ve written before, in the 15 years to 31 December 2011, he delivered a 347% return, versus the FTSE All‑Share’s distinctly more modest 42%.
 
And underpinning Mr Woodford’s performance were a series of choice picks of — yes! — those unloved, out-of-favour businesses, bought when others couldn’t get out of them fast enough.
 
Behemoths British American Tobacco and Imperial Tobacco, for instance, bought back in the late 1990s and early 2000s, when the market was convinced that massive tobacco lawsuits lay around the corner.
 
Or GlaxoSmithKline and AstraZeneca, bought when the market was convinced that both businesses had run out of patentable drug discoveries.
 
As Mr Woodford himself told the Daily Telegraph not so long ago:

“The investment industry is full of pseudo‑scientific mumbo‑jumbo, which confuses investors. But what I do is actually quite simple and can be communicated simply: my job is to look for anomalies in the values put on companies by the stock market. Some companies are undervalued by the market, some are overvalued. A fund manager’s job is to find the former, and avoid the latter.

Ignore the naysayers

All of which sounds quite simple and straightforward. Except that it isn’t.
 
Because going against the crowd — which is what contrarian investors do — is never comfortable. Simply put, you’re buying shares that everyone else is selling.
 
Moreover, just because a share is cheap, doesn’t mean that it won’t get cheaper still. So be prepared to stick to your guns and sit it out. Possibly for a lot longer than you’d expected.
 
And yet, the rewards are there.
 
As I said at the beginning: I’m rubbish at picking hot-shot growth stocks. But I like to think that I’m rather better at waiting for a generally well-managed business to recover from some temporary headwinds.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Malcolm owns shares in Compass, GKN, Greggs, GlaxoSmithKline, and AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »

Investing Articles

I’m expecting my Phoenix Group shares to give me a total return of 25% in 2025!

Phoenix Group shares have had a difficult few months but that doesn't worry Harvey Jones. He loves their 10%+ yield…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

14.5bn reasons why I think the Legal & General share price is at least 11% undervalued

According to our writer, the Legal & General share price doesn’t appear to reflect the underlying profitability of the business. 

Read more »